Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from gene editing

Biologist whose innovation saved the life of British teenager wins $3m Breakthrough prize

Prof David Liu is among the winners of 2025’s ‘Oscars of science’, with honours also going to researchers for landmark work on multiple sclerosis, particle physics and ‘skinny jabs’

The Guardian - UK

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

MarketBeat

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Benzinga

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA)

Benzinga

RNA editing is the next frontier in gene therapy – here’s what you need to know

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes vision loss in millions of older people worldwide.

The Conversation

Scientists dismayed as UK ministers clear way for gene editing of crops - but not animals

Advocates urge government to allow ‘precision breeding’ to combat disease, but RSPCA warns of ethical dangers

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

A Novel Discovery Hints At Why We Stop Producing New Brain Cells — And What We Can Do About It

A new study from Stanford Medicine shows how a gene editing tool identified a gene to knock out that could promote activation of neural stem cells.

Inverse

A Rose Without Thorns? How Gene Editing Is Giving Plants A Glow-Up

A geneticist recently discovered the gene that accounts for prickliness across a variety of plants, including roses.

Inverse

Plants get a GMO glow-up: Genetically modified varieties are coming out of the lab and into homes and gardens

As any avid gardener will tell you, plants with sharp thorns and prickles can leave you looking like you’ve had a run-in with an angry cat. Wouldn’t it be nice to rid plants of their prickles entirely but keep the tasty fruits and beautiful flowers?

The Conversation

Designer Babies Are Here — So Why Aren't We Talking About It?

The societal implications of this technology are still vast. And researchers can already start exploring the ethics by engaging communities well ahead of time.

Inverse

Editing fetal genomes is on the horizon

Why ethical discussions with the target communities should happen sooner rather than later

Salon

Editing fetal genomes is on the horizon − a medical anthropologist explains why ethical discussions with the target communities should happen sooner rather than later

With their primary goal to advance scientific knowledge, most scientists are not trained or incentivized to think through the societal implications of the technologies they are developing. Even in genomic medicine, which is geared toward benefiting future patients, time and funding pressures make real-time ethics oversight difficult.

The Conversation

3 Gene-Editing Stocks to Buy for Future Health Advances

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Top News

Genetic Enhancement Key To Future Of Space Travel, Experts Say

Explore the potential of genetic enhancements in humans for space travel and the ethical considerations surrounding gene editing technology.

The Conversation

TB: gene editing could add new power to a 100-year-old vaccine

Tuberculosis dates back more than 9,000 years. It is the most infectious bacterial disease and in 2022 10.6 million people fell ill with it. Of these 23% occurred in Africa.

Axios

Gene editing's next big targets

Scientists are pursuing advances to address the technology's limitations and stretch gene editing to treat different types of diseases, improve agriculture, livestock and more.

The Conversation

AI plus gene editing promises to shift biotech into high gear

During her chemistry Nobel Prize lecture in 2018, Frances Arnold said, “Today we can for all practical purposes read, write and edit any sequence of DNA, but we cannot compose it.” That isn’t true anymore.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

3 Cathie Wood Biotech Stocks That Analysts Expect to Double

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

StockNews.com

3 Biotech Stocks to Consider Buying Right Away

The biotechnology industry is thriving, fueled by solid government support, rising healthcare spending worldwide, gene editing breakthroughs, and rapid AI adoption. Hence, fundamentally solid biotech stocks Shionogi (SGIOY), United Therapeutics (UTHR), and SIGA Technologies (SIGA) could be ideal buys for potential gains. Keep reading….

The Guardian - UK

Gene-editing crops to be colourful could aid weeding, say scientists

Creating visually distinctive plants likely to become important as more weed-like crops are grown for food

The Guardian - AU

Scientist who gene-edited babies is back in lab and ‘proud’ of past work despite jailing

China’s He Jiankui, who used Crispr to edit genome, says he is working on genetic diseases and suggests human embryo gene editing will one day be accepted

Top News

Exploring The Top 10 Genetic Engineering Breakthroughs

Explore the latest breakthroughs in genetic engineering, from CRISPR-Cas9 to gene therapy, and their impact on healthcare and conservation.

Top News

Exploring The Top 10 Genomic Medicine Breakthroughs

Explore how genomic innovations are revolutionizing healthcare with precision gene editing and personalized treatments.

Top News

Advancements in AI, virtual reality, and gene editing will reshape society

Explore the biggest technology trends that are expected to shape our lives in the next 10 years, from AI integration and virtual reality to genetic enginee...

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Harvard Medical School

135 stories

BIIB

129 stories

Medical Pharmaceuticals

125 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.